Immune-modulating vaccines in non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 1, Issue 7, 2006, Pages 756-761

  Nemunaitis, John ^a   Murray, Nevin ^b  

^a Mary Crowley Medical Research Center   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIGEN; CANCER VACCINE; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HLA ANTIGEN; L BLP25 VACCINE; LIPOPEPTIDE; LUCANIX; PEMETREXED; PHOSPHORYL LIPID A; RAS ANTIGEN; RAS PROTEIN; RECOMBINANT VACCINE; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; BELAGENPUMATUCEL L; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; L BLP25; L-BLP25; MEMBRANE PROTEIN;

ABSENCE OF SIDE EFFECTS; ANTISENSE THERAPY; BYSTANDER EFFECT; CANCER IMMUNIZATION; CANCER SURVIVAL; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TREATMENT FAILURE; FATIGUE; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INJECTION SITE REACTION; LEUKOCYTOSIS; LUNG NON SMALL CELL CANCER; LYMPHOKINE ACTIVATED KILLER CELL; NAUSEA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLASMID; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN TARGETING; REVIEW; SACCHAROMYCES CEREVISIAE; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE; THORACOCENTESIS; TREATMENT OUTCOME; IMMUNOLOGY; LUNG TUMOR;

CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS;

EID: 34247891727     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200609000-00033     Document Type: Review

References (65)

1. Hege KM, Carbone DP. Lung cancer vaccines and gene therapy. Lung Cancer 2003;41(Suppl 1):S103-S113.
2. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-3543.
3. Scheffer SR, Nave H, Korangy F, et al. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer 2003;103:205-211.
4. Borrello I, Pardoll D. GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev 2002;13:185-193.
5. Jaffee EM, Thomas MC, Huang AY, Hauda KM, Levitsky HI, Pardoll DM. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J Immunother Emphasis Tumor Immunol 1996;19:176-183.
6. Couch M, Saunders JK, O'Malley BW Jr, Pardoll D, Jaffee E. Genetically engineered tumor cell vaccine in a head and neck cancer model. Laryngoscope 2003;113:552-556.
7. Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999;59:5160-5168.
8. Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998;95:13141-13146.
9. Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997;57:1537-1546.
10. Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001;19:145-156.
11. Salgia R, Lynch T, Skarin A, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 2003;21:624-630.
12. Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003;21:3343-3350.
13. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML. Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997;71:1842-1849.
14. Borrello I, Sotomayor EM, Cooke S, Levitsky HI. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther 1999;10:1983-1991.
15. Nemunaitis J, Jahan T, Ross H, et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX((R)) vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 2006;13:555-562.
16. Sporn MB, Roberts AB, Wakefield LM, Assoian RK. Transforming growth factor-beta: biological function and chemical structure. Science 1986;233:532-534.
17. Massague J. The TGF-beta family of growth and differentiation factors. Cell 1987;49:437-438.
18. Border WA, Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 1992;90:1-7.
19. Bodmer S, Strommer K, Frei K, et al. Immunosuppression and transforming growth factor-beta in glioblastoma: preferential production of transforming growth factor-beta 2. J Immunol 1989;143:3222-3229.
20. Jakowlew SB, Mathias A, Chung P, Moody TW. Expression of transforming growth factor beta ligand and receptor messenger RNAs in lung cancer cell lines. Cell Growth Differ 1995;6:465-476.
21. Constam DB, Philipp J, Malipiero UV, ten Dijke P, Schachner M, Fontana A. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol 1992;148:1404-1410.
22. Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS. Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 1999;86:1712-1719.
23. Rook AH, Kehrl JH, Wakefield LM, et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986;136:3916-3920.
24. Kasid A, Bell GI, Director EP. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors: autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J Immunol 1988;141:690-698.
25. Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature 1988;334:260-262.
26. Hirte H, Clark DA. Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor. Cancer Immunol Immunother 1991;32:296-302.
27. Naganuma H, Sasaki A, Satoh E, et al. Transforming growth factor-beta inhibits interferon-gamma secretion by lymphokine-activated killer cells stimulated with tumor cells. Neurol Med Chir (Tokyo) 1996;36:789-795.
28. Ruffini PA, Rivoltini L, Silvani A, Boiardi A, Parmiani G. Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol Immunother 1993;36:409-416.
29. Fakhrai H, Mantil JC, Liu L, et al. Phase I clinical trial of TGF-β antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther. In press.
30. Liau LM, Fakhrai H, Black KL. Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene. Neurol Res 1998;20:742-747.
31. Dorigo O, Shawler DL, Royston I, Sobol RE, Berek JS, Fakhrai H. Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model. Gynecol Oncol 1998;71:204-210.
32. Tzai TS, Shiau AL, Liu LL, Wu CL. Immunization with TGF-beta antisense oligonucleotide-modified autologous tumor vaccine enhances the antitumor immunity of MBT-2 tumor-bearing mice through upregulation of MHC class I and Fas expressions. Anticancer Res 2000;20:1557-1562.
33. Tzai TS, Lin CI, Shiau AL, Wu CL. Antisense oligonucleotide specific for transforming growth factor-beta 1 inhibit both in vitro and in vivo growth of MBT-2 murine bladder cancer. Anticancer Res 1998;18:1585-1589.
34. Marzo AL, Fitzpatrick DR, Robinson BW, Scott B. Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res 1997;57:3200-3207.
35. Park JA, Wang E, Kurt RA, Schluter SF, Hersh EM, Akporiaye ET. Expression of an antisense transforming growth factor-beta1 transgene reduces tumorigenicity of EMT6 mammary tumor cells. Cancer Gene Ther 1997;4:42-50.
36. Kettering JD, Mohamedali AM, Green LM, Gridley DS. IL-2 gene and antisense TGF-beta1 strategies counteract HSV-2 transformed tumor progression. Technol Cancer Res Treat 2003;2:211-221.
37. Fakhrai H, Dorigo O, Shawler DL, et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 1996;93:2909-2914.
38. Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of Lucanix™ a transforming growth factor (TGF-2) antisense gene modified allogeneic tumor cell vaccine in non small cell lung cancer (NSCLC). J Clin Oncol In Press.
39. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
40. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362.
41. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
42. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 2006;353:133-144.
43. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2006;353:123-132.
44. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158.
45. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984;3:223-232.
46. Burchell J, Gendler S, Taylor-Papadimitriou J, et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987;47:5476-5482.
47. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990;265:15286-15293.
48. Li Y, Liu D, Chen D, Kharbanda S, Kufe D. Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 2003;22:6107-6110.
49. Ren J, Agata N, Chen D, et al. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004;5:163-175.
50. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-651.
51. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 1998;4:43-49.
52. MacLean GD, Reddish MA, Koganty RR, Longenecker BM. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol 1996;19:59-68.
53. Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2006;23:6674-6681.
54. Stubbs AC, Martin KS, Coeshott C, et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 2001;7:625-629.
55. Lu Y, Bellgrau D, Dwyer-Nield LD, et al. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res 2004;64:5084-5088.
56. Salgaller ML. The development of immunotherapies for non-small cell lung cancer. Expert Opin Biol Ther 2002;2:265-278.
57. Ratto GB, Zino P, Mirabelli S, et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer 1996;78:244-251.
58. Lissoni P, Meregalli S, Fossati V, et al. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer. Tumori 1994;80:464-467.
59. Ratto GB, Cafferata MA, Scolaro T, et al. Phase II study of combined immunotherapy, chemotherapy, and radiotherapy in the postoperative treatment of advanced non-small-cell lung cancer. J Immunother 2000;23:161-167.
60. Nemunaitis J. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev Vaccines 2006;4:259-274.
61. Nemunaitis J, Sterman D, Jablons D, et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 2004;96:326-331.
62. Morse MA. Technology evaluation: BLP-25, Biomira Inc. Curr Opin Mol Ther 2001;3:102-105.
63. Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 2004;22:2808-2815.
64. Raez LE, Cassileth PA, Schlesselman JJ, et al. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:2800-2807.
65. Nemunaitis J, Meyers T, Senzer N, et al. Phase I trial of sequential administration of recombinant DNA and adenoviral expressing L523S protein in early stage non small cell lung cancer (NSCLC). Mol Ther 2006;13:1185-1191.